-
Barclays Upgrades ZimVie Inc. (ZIMV) to Equalweight
-
ARCHIMED to acquire ZimVie for $19 per share in $730 million deal
-
ZimVie Inc. (ZIMV) PT Lowered to $10 at UBS
-
Needham Reiterates Hold Rating on ZimVie Inc. (ZIMV)
-
ZimVie Inc. (ZIMV) Tops Q1 EPS by 5c
-
B.Riley Starts ZimVie Inc. (ZIMV) at Buy
-
ZimVie Inc. (ZIMV) Announces Board Changes
-
Needham Downgrades ZimVie Inc. (ZIMV) to Hold
-
Needham Downgrades DENTSPLY SIRONA (XRAY) to Hold
-
ZimVie Inc. (ZIMV) Tops Q4 EPS by 1c ; Offers Guidance
-
ZimVie Inc. (ZIMV) Misses Q2 EPS by 4c
-
ZimVie Inc. (ZIMV) Announces FDA Clearance and U.S. Launch of GenTek Restorative Components
-
ZimVie (ZIMV) is in Advanced Talks to be Acquired by Osstem Implant - Bloomberg
-
ZimVie Inc. (ZIMV) call put ratio 6.5 calls to 1 put with a focus on July 15 and 20 calls
-
ZimVie (ZIMV) could be worth $25-29 per share in a potential acquisition - Needham & Company
-
ZimVie (ZIMV) reiterated at Buy by Needham on takeover rumors, 'ZIMV could be worth $25-29 per share'
-
ZimVie (ZIMV) Said To Weigh Options Including Potential Sale - Bloomberg

